{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:30:45Z","timestamp":1786465845156,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40262-026-01663-z","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:35:16Z","timestamp":1781361316000},"page":"1173-1192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elranatamab Population Pharmacokinetics and Exposure\u2013Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6547-2186","authenticated-orcid":false,"given":"Jennifer E.","family":"Hibma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Irby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elmeliegy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay E.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gifondorwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamrine E.","family":"Poels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooneh","family":"Soltantabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Kei","family":"Lon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blerta","family":"Shtylla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason H.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"issue":"27-28","key":"1663_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3238\/arztebl.2016.0470","volume":"113","author":"C Gerecke","year":"2016","unstructured":"Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S. The diagnosis and treatment of multiple myeloma. Dtsch Arztebl Int. 2016;113(27\u201328):470\u20136. https:\/\/doi.org\/10.3238\/arztebl.2016.0470.","journal-title":"Dtsch Arztebl Int"},{"issue":"12","key":"1663_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u2013548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1663_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046\u201360. https:\/\/doi.org\/10.1056\/NEJMra1011442.","journal-title":"N Engl J Med"},{"issue":"7","key":"1663_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.clml.2022.01.011","volume":"22","author":"MA Dimopoulos","year":"2022","unstructured":"Dimopoulos MA, Richardson P, Lonial S. Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022;22(7):460\u201373. https:\/\/doi.org\/10.1016\/j.clml.2022.01.011.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"1663_CR5","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","volume":"33","author":"AH Bazarbachi","year":"2019","unstructured":"Bazarbachi AH, Al Hamed R, Malard F, Harousseau J-L, Mohty M. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019;33(10):2343\u201357. https:\/\/doi.org\/10.1038\/s41375-019-0561-2.","journal-title":"Leukemia"},{"key":"1663_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01675-5","volume":"18","author":"H Zheng","year":"2025","unstructured":"Zheng H, Xian H, Zhan W, et al. BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting. J Hematol Oncol. 2025;18:23. https:\/\/doi.org\/10.1186\/s13045-025-01675-5.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"1663_CR7","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29(10):2570\u20136. https:\/\/doi.org\/10.1038\/s41591-023-02589-w.","journal-title":"Nat Med"},{"key":"1663_CR8","unstructured":"Elrexfio (elranatamab-bcmm). Prescribing information. Pfizer; 2026."},{"issue":"6","key":"1663_CR9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cpt.3533","volume":"117","author":"D Irby","year":"2025","unstructured":"Irby D, Hibma J, Elmeliegy M, et al. A novel two-part mixture model for the incidence and time course of cytokine release syndrome after elranatamab dosing in multiple myeloma patients. Clin Pharmacol Ther. 2025;117(6):1687\u201395. https:\/\/doi.org\/10.1002\/cpt.3533.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1663_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.70130","volume":"66","author":"P Soltantabar","year":"2026","unstructured":"Soltantabar P, Hibma J, Wang D, Conte U, Hickman A, Elmeliegy M. Elranatamab exposure-safety analysis in relapsed or refractory multiple myeloma. J Clin Pharmacol. 2026;66(1):e70130. https:\/\/doi.org\/10.1002\/jcph.70130.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1663_CR11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11523-025-01168-y","volume":"20","author":"H-K Lon","year":"2025","unstructured":"Lon H-K, Hibma J, Jiang S, et al. Population exposure-response efficacy analysis of elranatamab (PF-06863135) in patients with multiple myeloma. Target Oncol. 2025;20(5):803\u201319. https:\/\/doi.org\/10.1007\/s11523-025-01168-y.","journal-title":"Target Oncol"},{"issue":"9","key":"1663_CR12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/jjco\/hyae068","volume":"54","author":"S Iida","year":"2024","unstructured":"Iida S, Ito S, Yokoyama H, Ishida T, Nagai Y, Handa H, et al. Elranatamab in Japanese patients with relapsed\/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3. Jpn J Clin Oncol. 2024;54(9):991\u20131000. https:\/\/doi.org\/10.1093\/jjco\/hyae068.","journal-title":"Jpn J Clin Oncol"},{"issue":"9","key":"1663_CR13","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"key":"1663_CR14","unstructured":"ClinicalTrials.gov. Indentifier: NCT05014412. A study to learn about the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment or has not responded to treatment (MagnetisMM-9). Updated February 10, 2026. Accesssed February 20, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05014412."},{"key":"1663_CR15","unstructured":"Food and Drug Administration Guidance for Industry: Immunogenicity Testing of Therapeutic Protein Products\u2014Developing and Validating Assays for Anti-Drug Antibody Detection. 2019. Accessed February 20, 2026. https:\/\/www.fda.gov\/media\/119788\/download."},{"key":"1663_CR16","unstructured":"European Medicines Agency. Guideline on Immunogenicity Assessment of Therapeutic Proteins (Rev. 1). 2017. Accessed February 20, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf."},{"issue":"5","key":"1663_CR17","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/j.1365-2125.2006.02803.x","volume":"63","author":"N Hayashi","year":"2007","unstructured":"Hayashi N, Tsukamoto Y, Sallas W, Lowe P. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007;63(5):548\u201361. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02803.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1663_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1023\/a:1011527125570","volume":"28","author":"U W\u00e4hlby","year":"2001","unstructured":"W\u00e4hlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28(3):231\u201352. https:\/\/doi.org\/10.1023\/a:1011527125570.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9","key":"1663_CR19","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1023\/a:1011970125687","volume":"15","author":"EN Jonsson","year":"1998","unstructured":"Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998;15(9):1463\u20138. https:\/\/doi.org\/10.1023\/a:1011970125687.","journal-title":"Pharm Res"},{"issue":"7","key":"1663_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.26","volume":"2","author":"W Byon","year":"2013","unstructured":"Byon W, Smith MK, Chan P, et al. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacomet Syst Pharmacol. 2013;2(7):e51. https:\/\/doi.org\/10.1038\/psp.2013.26.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"Suppl 1","key":"1663_CR21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208192","volume":"144","author":"HM Prince","year":"2024","unstructured":"Prince HM, Bahlis NJ, Rodr\u00edguez-Otero P, et al. MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma. Blood. 2024;144(Suppl 1):4738. https:\/\/doi.org\/10.1182\/blood-2024-208192.","journal-title":"Blood"},{"issue":"10","key":"1663_CR22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"N Dirks","year":"2010","unstructured":"Dirks N, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633\u201359. https:\/\/doi.org\/10.2165\/11535960-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1663_CR23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","volume":"18","author":"X Miao","year":"2023","unstructured":"Miao X, Wu LS, Wang SX, et al. Population pharmacokinetics and exposure\u2013response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1. Target Oncol. 2023;18(5):667\u201384. https:\/\/doi.org\/10.1007\/s11523-023-00989-z.","journal-title":"Target Oncol"},{"issue":"3","key":"1663_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/psp4.12369","volume":"8","author":"J Schropp","year":"2019","unstructured":"Schropp J, Khot A, Shah DK, Koch G. Target-mediated drug disposition model for bispecific antibodies: properties, approximation, and optimal dosing strategy. CPT Pharmacomet Syst Pharmacol. 2019;8(3):177\u201387. https:\/\/doi.org\/10.1002\/psp4.12369.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"6","key":"1663_CR25","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/psp4.41","volume":"4","author":"P Dua","year":"2015","unstructured":"Dua P, Hawkins E, van der Graaf PH. A tutorial on target-mediated drug disposition (TMDD) models. CPT Pharmacomet Syst Pharmacol. 2015;4(6):324\u201337. https:\/\/doi.org\/10.1002\/psp4.41.","journal-title":"CPT Pharmacomet Syst Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01663-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01663-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01663-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:17:09Z","timestamp":1786461429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01663-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1663"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01663-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflict of Interest\n                      J.E.H., D.I., A.L., M.E., L.E.K., D.G., S.J., K.E.P., P.S., H.-K.L., B.S., and T.N. are full-time employees of Pfizer, Inc., and own Pfizer stock. D.W. and J.W were full-time employees of Pfizer, Inc. at the time of conducting this analysis and may own Pfizer stock.","order":1,"name":"Ethics","label":"Declarations","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See\n                      \n                      for more information. Model scripts may be made available upon reasonable request to the corresponding author.","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Each study site\u2019s local independent ethics committee or institutional review board approved the study protocol. The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All patients provided written informed consent.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Written informed consent was obtained from all participants prior to study participation.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}